The Benefits of Immunization for High-Risk Populations

Download PDF

Last year’s availability of respiratory syncytial virus (RSV) vaccines marked a critical step in science and public health. Previously, no widespread prevention option existed to protect those at increased risk for RSV, including older adults, from this serious infectious respiratory disease. In the year since RSV vaccines were first introduced, real world evidence has shown that they are effective in preventing serious illness for individuals 60 years and older. However, despite the progress made towards RSV prevention, RSV vaccine uptake continues to remain low in older adults.

As we continue into peak respiratory season and beyond, CVEEP hosted an expert-led conversation on updated risk-based RSV vaccine guidance for older adults, the value of vaccination for adults at highest risk for severe RSV disease, and other important considerations to help promote vaccine uptake across communities.

Speakers included:

• Amadea Britton, MD, Medical Officer, Coronavirus and Other Respiratory Viruses Division, Co-Lead of the Advisory Committee on Immunization Practices Adult RSV Vaccine Work Group, Centers for Disease Control and Prevention
• Lynn Albizo, JD, Chief Public Policy Officer at the Immune Deficiency Foundation
• Sara Maloney, MPA, Program Director of the Aging and Disability Vaccination Collaborative and the Center for Dementia Respite Innovation, USAging

The discussion was moderated by Karyne Jones, President and Chief Executive Officer of the National Caucus and Center on Black Aging, a convener of CVEEP.

Preparing for Respiratory Illness Season: A Guide for Long-term Care

Download PDF

Posters: Stay Updated on COVID-19 and Flu Vaccines

Download PDF

Make Your Vaccine Plan: A Checklist for Staying Protected

Download PDF

FAQ: Getting Your COVID-19 and Flu Vaccines This Respiratory Season

Download PDF

What to Know About Maternal Vaccination

Download PDF

Infectious Respiratory Disease Vaccine Recommendations

Download PDF

FAQ About Respiratory Disease Season

Download PDF

As respiratory illness season is now underway, it’s crucial for healthcare professionals and the public to stay informed on the latest guidance regarding COVID-19, flu, and RSV vaccines. The first featured a fireside chat featuring Dr. Peter Marks of the FDA, who shared key regulatory updates and highlighted the critical role of vaccines in preventing severe illness during respiratory season and beyond.

Following the fireside chat, a panel of experts analyzed the recent summer COVID-19 surge and outline what individuals need to know about receiving their updated vaccines. The panel also discussed the safety, efficacy, and feasibility of co-administering the COVID-19, flu, and RSV vaccines, while examining the current trends in vaccine uptake. By stressing the importance of timely vaccination, the panelists offered practical insights and strategies to ensure widespread protection this fall.

Panelists include:

• Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research (CBER), FDA
• Uché Blackstock, MD, Emergency Physician, Founder & CEO of Advancing Health Equity
• Synovia Moss, MPA, CEO/Managing Partner, Moss Consulting & Management Group, National Project Manager, Good Health Women’s Immunization Networks (Good Health WINs), National Council of Negro Women
• Kayla McFeely, PharmD, Vice President, Pharmacy Care, Health & Wellness Programs, National Association of Chain Drug Stores (NACDS)
• Sue Peschin, MS, President and CEO, Alliance for Aging Research (moderator)